Fluor Builds Diabetes API Manufacturing Facility for Novo Nordisk

| December 21, 2016

article image
Fluor announced on Dec. 20, 2016 that it had been awarded an engineering, procurement, construction, and construction management contract by Novo Nordisk to build a new $2-billion 830,00-sq.-ft. diabetes API manufacturing facility in Clayton, North Carolina. Construction on the new facility is expected to be completed in mid-2019.

Spotlight

Obagi Medical Products

Obagi Medical Products, Inc., a division of Valeant Pharmaceuticals North America, is a specialty pharmaceutical company that develops, markets and sells, and is the leading provider of proprietary topical aesthetic and therapeutic clinically-proven skin care systems in the physician-dispense market. The systems are designed to prevent and improve the most common and visible skin disorders. The foundation of the company began in 1988 with the creation of the Obagi Nu-Derm® System, developed by leading skin care experts. In 1997 the company officially began operations as Obagi Medical Products, Inc.

OTHER ARTICLES

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | March 11, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More
PHARMACY MARKET

A pharma outsourcing mission

Article | March 11, 2020

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

Pricing of drugs – at what cost?

Article | March 11, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

Pharmacist eCare Plan - the newest disrupter in health data exchange?

Article | March 11, 2020

Every member of the health care team shares a common goal of optimizing patient outcomes. Yet each specialty and position of the healthcare team has a unique workflow facilitated by various tools, from an operative report to a progress note. In this regard the pharmacist plays a pivotal function in medication management and requires documentation specific to that role. The Pharmacist eCare Plan (PeCP) allows for an interoperable note to be used in the pharmacy to assist in the exchange of patient information, including active medication list, laboratory results, and payer information. To allow for this, a new type of clinical document architecture for the PeCP was created and standardized for use across pharmacies.

Read More

Spotlight

Obagi Medical Products

Obagi Medical Products, Inc., a division of Valeant Pharmaceuticals North America, is a specialty pharmaceutical company that develops, markets and sells, and is the leading provider of proprietary topical aesthetic and therapeutic clinically-proven skin care systems in the physician-dispense market. The systems are designed to prevent and improve the most common and visible skin disorders. The foundation of the company began in 1988 with the creation of the Obagi Nu-Derm® System, developed by leading skin care experts. In 1997 the company officially began operations as Obagi Medical Products, Inc.

Events